Results 281 to 290 of about 322,522 (351)

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky   +8 more
wiley   +1 more source

Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union-a comparative overview. [PDF]

open access: yesESMO Open
Kahles A   +13 more
europepmc   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Global landscape and professionalization of infection preventionist education: comparative insights and future directions. [PDF]

open access: yesFront Public Health
Cao YL   +8 more
europepmc   +1 more source

The future of Italian phase I trials regulation: lessons from a nationwide survey. [PDF]

open access: yesFront Med (Lausanne)
Cagnazzo C   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy